Bruce E. Brockstein, MDDepartment of Medicine
Medical Director, Kellogg Cancer Centers 


  • Undergraduate:  BS, Mechanical Engineering, University of Illinois, Urbana, IL
  • Medical School:  MD, Medicine, University of Chicago, Chicago, IL
  • Residency: Internal Medicine, Hospital of the University of Pennsylvania
  • Fellowship:  Hematology/Oncology, University of Chicago, Chicago, IL

Research Interests

  • Head and Neck Cancers
  • Sarcoma
  • Melanoma

 Professional Memberships/Affiliations/Activities

  •  (1996-1998) Instructor of Clinical Medicine, University of Chicago, Department of Internal Medicine
  • (1998-1999) Assistant Professor of Clinical Medicine, University of Chicago, Department of Internal Medicine
  • (1999-present) Attending Staff, Evanston Hospital, Evanston, IL

Scholarly Work

Publications in Peer-Review Journals:

  1. Brockstein BE, Ross AA, Moss TJ, Kahn DG, Hollingsworth K, Williams SF.  Tumor Cell Contamination of Bone Marrow Harvest Products:  Clinical Consequences in a  Cohort of Advanced Stage Breast Cancer Patients Undergoing  High Dose Chemotherapy. J Hematotherapy 1996; 5:617-624.
  2. Brockstein B, Haraf D, Stenson K, Fasammade A, Stupp R, Glisson B, Lippman S, Sulzen L, Klepsch A, Ratain M, Weichselbaum R, Vokes EE.  A Phase I Study of Intensive Concomitant Chemotherapy with Paclitaxel, 5FU, and Hydroxyurea with Granulocyle Colony Stimulating Factor Support for Patients with Advanced Cancer of the Head and Neck.  Journal of Clinical Oncology, 1998; 16:735
  3. Vogelzang NJ, Mani S, Schilsky RL, Ansari RH, Taber D, Rhinehart SN, Garcia JC, Meyer SC, Mick R, Brockstein BE, Stadler WM, Ratain MJ, and Vokes EE.  Phase II and Pharmacodynamic studies of Pyrazine Diazohydroxide (NSC 361456) in Patients with Advanced Renal and Colorectal Cancer.  Clinical Cancer Research, 1998; 4:929-934.
  4. Humerickhouse RA, Dolan ME, Haraf DJ, Brockstein B, Stenson K, Kies M, Sulzen L, Ratain MJ, Vokes EE.  Phase I Study of Eniluracil, A Dihydropyrimidine Dehydrogenase Inhibitor, and Oral 5-FU with Radiation Therapy In Patients with Recurrent Or Advanced Head and Neck Cancer. Clin Ca Rsch 1999;5:291-8
  5. Lamont E, Cavaghan M, Brockstein BOncogenic Osteomalacia as a Harbinger of recurrent Osteosarcoma. Sarcoma, 1999;3:95-100.
  6. Brockstein B, Shepard D, Kugler J, Fishkin, , Arrieta R,  Ratain M,  Vokes, EE, Vogelzang NJ.  A Phase II Study of Trimethylcolchinicinic Acid in Advanced Prostate Cancer. The Prostate Journal 1999;1:195-202.
  7. Stenson KM, MacCracken E, List M, Haraf DJ, Brockstein B, Weichselbaum R, Vokes EE.  Swallowing function in head and neck cancer patients prior to treatment. Archives of Otolaryngology, Head and Neck Surgery 2000;126:371-377.
  8. Brockstein B, Smiley C, Al-Sadir J, Williams S. Cardiac and pulmonary t oxicityin patients undergoing high dose chemotherapyfor lymhoma and breast cancer: prognostic factors. Bone Marrow Transplantation 2000;25:885-894.
  9. Brockstein B, Haraf DJ, Stenson K, Sulzen L, Witt ME, Weichselbaum RW, Vokes EE.  A phase I/II study of concomitant chemoradiotherapy with paclitaxel (1 hour infusion), 5FU, and hydroxyurea with granulocyte colony stimulating factor support for patients with poor prognosis head and neck cancer. Annals of Oncology 2000;11:721-728.
  10. Brockstein BBenefits of chemotherapy in head and neck cancer. (Letter) Lancet 2000;356:767.
  11. Lad T, Rosen F, Sciortino D, Brockstein B, Keubler JP, Arietta R, Vokes E. Phase II Trial of Aminocamptothecin (9-AC/DMA) in Patients with Advanced Squamous Cell Head and Neck Cancer. Invest New Drugs 2000;18:261-263.
  12. Brockstein BEReduction of distant metastases in head and neck cancer with concomitant chemotherapy. (Letter). J Clin Oncol 2000; 18:3320
  13. Brockstein B, Samuels B, Humerickhouse R, Arietta , Fishkin P, Wade J, Sosman J, Vokes EE.  Phase II Studies of Bryostatin-1 in Patients with Advanced Sarcoma and Advanced Head and Neck Cancer. Investigational New Drugs 2001;19:249-254.
  14. Pfister DG, Ang K, Brockstein B, Colevas AD, Ellerhorn J, Goepfert H, et al.  NCCN Practice Guidelines for Head and Neck Cancers.  Oncology (Huntingt) 2000; 14(11A):163-194.
  15. Sener SF, Milos S, Feldman J, Martz CH, Winchester DJ, Dieterich M, Locker G, Khandekar JD, Brockstein B, Haid,M.- The Spectrum of Vascular Lesions in the Mammary Skin, Including Angiosarcoma, after Breast Conservation Treatment for Breast Cancer.  J Am Coll Surg 2001;193:22-28.
  16. Kies MS, Haraf DJ, Rosen F, Stenson K, List M, Brockstein B, Chung T, Mittal BB, Pelzer H, Portugal L, Rademaker A, Weichselbaum R, Vokes EE. Concomitant Infusional Paclitaxel and Fluorouracil, oral Hydroxyurea, and Hyperfractionated Radiation for Locally Advanced Squamous Head and Neck Cancer.  J Clin Oncol 2001;19:1961-1969.
  17. Masters GA, Brockstein B, Mani S, Ratain M.  Phase I Dose Escalation Study of Docetaxel with Filgrastim Support in Patients with Solid Tumors. Medical Oncolgy 2003;20:7-12
  18. Vokes EE, Stenson, Rosen FR, Kies MS, Rademaker AW, Witt ME, Brockstein BE, List MA, Fung BB, Portugal L, Mittal BB, Pelzer H, Weichselbaum RR, Haraf DJ.  Weekly carboplatin followed by concomitant TFHX chemoradiotherapy: Curative and Organ Preserving Therapy for Advanced Head and Neck Cancer. J Clin Oncol 2003;21;320-326.
  19. Rosen FR, Haraf DJ, Kies MS, Stenson K, Portugal L, List MA, Brockstein BE, Mittal BB, Rademaker AW, Witt ME, Pelzer H, Weichselbaum RR, Vokes EE.  Multicenter Randomized Phase II Study of Paclitaxel (1 hour infusion), fluorouracil, hydroxyurea and concomitant twice daily radiation with or without erythropoietin for advanced head and neck cancer. Clinical Cancer Research 2003;9:1689-1697.
  20. Lamont E, Hayreh D, Pickett K, List M, Stenson K, Haraf D, Brockstein B, Sellergren SA, Vokes E.  Is travel distance associated with survival on phase II trials in oncology?  J Natl Cancer Inst 2003;95:1370-1375
  21. Brockstein B, Mundt AJ, Haraf DJ, Ferguson M, Montag A.  Radiation induced Leiomyosarcoma. Does antimetabolite chemotherapy contribute?  A report of three cases. Sarcoma 2003;7:167-172
  22. Haraf DJ, Rosen FR, Stenson K, Argiris A, Mittal BB, Witt ME, Brockstein BE, List MA, Pelzer H, Weichselbaum RR, Vokes EE. Induction chemotherapy followed by concomitant TFHX chemoradiotherapy with reduced dose radiation in advanced head and neck cancer. Clin Cancer Res 2003;9:5936-5943.
  23. Argiris A, Brockstein BE, Stenson KM, Mittal BB, Kies MS, Portugal L, Wenig BL, Rosen FR, Haraf DJ, Vokes EE.  Competing causes of death and second primary tumors with locoregionally advanced head and neck cancer treated with chemoradiotherapy. Clin Cancer Res 2004;10:1956-1962.
  24. Brockstein B, Haraf DJ, Rademaker AW, Kies MS, Stenson KM, Rosen FR, Mittal BB, Pelzer H, Fung BB, Rosen F, Witt ME, Wenig B, Portugal L, Weichselbaum RW. Vokes E. Patterns of failure, Prognostic Factors, and Survival in Locoregionally Advanced Head and Neck Cancer Treated with Organ Preservation Chemoradiotherapy. Ann Oncol 2004;15:1179-86
  25. Argiris A, Stenson KM, Brockstein BE, Mittal BB, Pelzer H, Kies MS, Jayaram P, Portugal L, Wenig BL, Rosen FR, Haraf DJ, Vokes EE.  Neck node dissection in the combined modality therapy of patients with locoregionally advanced head and neck cancer.  Head Neck. 2004;26:447-55.

Book Chapters:

  1. Brockstein BE, Vogelzang NJ. Chemotherapy of Genitourinary Cancer.  In Perry MC, ed:  The Chemotherapy Sourcebook, Second Edition   Baltimore, Williams and Wilkins, 1996. 1215-1251.
  2. Brockstein BE, Vokes EE.  Principles of Chemotherapy in Treating Head and Neck Cancer.  In Bailey BJ ed. Head and Neck Surgery- Otolaryngology, second ed., Philadelphia, Lippincott-Raven, 1998.
  3. Brockstein BE, Peabody T, Simon M.  Diagnosis and Treatment of Soft Tissue Sarcomas.  In Oncologic Therapies, Vokes EE, Golomb HM, eds.  Springer-Verlag, 1998.
  4. Peabody T, Brockstein B, Simon M.  Diagnosis and Treatment of Bone Sarcomas.  In Oncologic Therapies, Vokes EE, Golomb HM, eds Springer-Verlag, 1998.
  5. Brockstein BE, Vokes EE,  Chapter Editors.  Head and Neck Cancer.  In Up to Date (CDRom Textbook), B.D. Rose, editor.  Ongoing editorial duties include three times yearly updates and reviews of 40 sub-sections:

    Sections authored:

    • General Aspects of Induction Chemotherapy for Head and Neck Cancer -Brockstein/Vokes
    • Induction Chemotherapy for Organ Preservation in Head and Neck Cancer Brockstein/Vokes
    • General Aspects of Concurrent Chemoradiotherapy for Head and Neck Cancer Brockstein/Vokes
    • Concomitant Chemoradiotherapy for Unresectable Head and Neck Cancer Brockstein/Vokes
    • Concomitant Chemoradiotherapy for Resectable Head and Neck Cancer-Organ Preservation Brockstein/Vokes
    • Chemotherapy for Head and Neck Cancer: Single Agents- Brockstein/Vokes
    • Combination Chemotherapy for Head and Neck Cancer -Brockstein/Vokes
    • Nasopharyngeal Cancer -co-author, Gary Gordon
    • Complications of Concomitant Chemoradiotherapy for Head and Neck Cancer -Brockstein/Vokes
    • Imaging in Head and Neck Cancer- co-author Vivek Seghal
    • Head and Neck Sarcomas

  6. Brockstein BE, Vokes EE.  Principles of Chemotherapy in Treating Head and Neck Cancer.  In Bailey BJ ed. Head and Neck Surgery- Otolaryngology, third. ed, Philadelphia, Lippincott-Raven, 2001.
  7. Brockstein BE, Khandekar J, Chemotherapy for Head and Ncek Cancer. Chapter 57. In JJ Ballenger and JB Snow Jr. eds. Otorhinolaryngology, Head and Neck Surgery, 16th ed., Singular Publishers, San Diego, CA , 2003.

Proceedings and Non-Refereed Papers:

  1. Brockstein B, Johns L, Gewertz B.  Blood Supply to the Spinal Cord.  Anatomic and Physiological Correlation.  Annals of Vascular Surgery 1994; 8:394-399.
  2. Brockstein B, Williams S.  High Dose Chemotherapy with Autologous Stem Cell Rescue for Breast Cancer: Yesterday, Today, and Tomorrow. Stem Cells 1996; 14:79-89
  3. Brockstein B, Vokes EE.  Chemoradiotherapy for Head and Neck Cancer.  PPO Updates 1996; 10(9): 1-19.
  4. Vokes, EE, Brockstein BE, Humerickhouse R, Haraf DJ.  Oral 5-FU Alternatives for the Treatment of Head and Neck Cancer.  Oncology, 1998; 12(10 suppl 7):35-38.
  5. Brockstein BE, Vokes EE.  Concomitant and Rapidly Alternating Chemoradiation for Head and Neck Cancer.  Advances in Oncology, 1998 ;14:8-15.
  6. Brockstein BNew Sytstemic Therapeutic Strategies for Head and Neck Cancer.  Revisita de Oncologia. 1999;1:13-17.
  7. Vokes EE, Haraf DJ, Brockstein BE, Weichselbaum RR.   Paclitaxel, Fluorouracil, Hydroxyurea and Concomitant Radiation Therapy for Poor Prognosis  Head and Neck Cancer.  Semin Radiat Oncol, 1999;9(2 Suppl 1):70-76.
  8. Wolf GT, Forastiere A, Ang K, Brockstein B, Conley B, Goepfert H, Krause D, Lefebvre JL, Pajak T, Pfister D, Urba S.  Organ preservation strategies in advanced head and neck cancer: Current status and future directions.  Fifth Research Workshop on the Biology, Prevention and Treatment of Head and Neck Cancer, McLean, VA., August 27-30, 1998. Head Neck 1999;21:689-693.
  9. Brockstein BE, Vokes EE.  Oral Chemotherapy in Head and Neck Cancer.  Drugs 1999;58:91-97.
  10. Brockstein BIntegration of Taxanes into primary chemotherapy for squamous carcinoma of the head and neck- Promise fulfilled?  Current Opinion in Oncolgy 2000;12:221-228.
  11. Brockstein B, Vokes EE. Concurrent Chemoradiotherapy for Head and Neck Cancer.  Seminars in Oncology.  2004;13:786-793.
  12. Brockstein B.  Management of sarcomas of the head and neck.  Curr Oncol Rep. 2004;6:321-7.
× Alternate Text